Protein / target
Type-1 angiotensin II receptor
Protein at a glance
Biological role
Angiotensin type II receptor activity
Primary system
Immune system
Strongest disease association
renal tubular dysgenesis of genetic origin
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
22 approved · 2 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney (PubMed:15611106, PubMed:1567413, PubMed:25913193, PubMed:26420482, PubMed:30639100, PubMed:32079768, PubMed:8987975). The activated receptor in turn couples to G-alpha proteins G(q) (GNAQ, GNA11, GNA14 or GNA15) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C (PubMed:15611106)
Subcellular location
Domains and Gene Ontology detail (33)Hide
Gene Ontology
- Cmembrane
- Cplasma membrane
- Fangiotensin type I receptor activity
- Fangiotensin type II receptor activity
- Fbradykinin receptor binding
- Fprotein heterodimerization activity
- Pangiotensin-activated signaling pathway
- Pblood vessel diameter maintenance
- Pcalcium-mediated signaling
- Pcell chemotaxis
- PG protein-coupled receptor signaling pathway
- Pinflammatory response
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·inflammatory response
- ·positive regulation of inflammatory response
- ·regulation of inflammatory response
- ·symbiont entry into host cell
G protein-coupled signalling
- ·G protein-coupled receptor signaling pathway
- ·phospholipase C-activating G protein-coupled receptor signaling pathway
Metabolic enzyme activity
- ·positive regulation of cholesterol metabolic process
- ·positive regulation of reactive oxygen species metabolic process
Kinase signalling
- ·Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator o…
View underlying pathways (4)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Type-1 angiotensin II receptor antagonist
Appears in clinical studies involving congestive heart failure, heart failure, myocardial infarction, hypertensive disorder
Type-1 angiotensin II receptor antagonist
Appears in clinical studies involving Hypertension, cardiovascular disorder, chronic kidney disease, hemorrhagic stroke
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Show all associationsHide all associations
Open Targets ranks 1,493 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 24 total
cardiovascular disorder · Increased blood pressure · septic shock
Hypertension
congestive heart failure · heart failure · myocardial infarction
cardiovascular disorder · essential hypertension · Hypertension
hypertensive disorder · stroke disorder · Hypertension
COVID-19 · heart failure · heart failure
Shock · hypotensive disorder · septic shock
Hypertension
hypertensive disorder · Hypertension · stroke disorder
Hypertension
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- New publicationCardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.
- New publicationMulticenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
- New publicationAmbulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination.
- New publicationAngiotensin-neprilysin inhibition versus enalapril in heart failure.
- New publicationEfficacy and safety of valsartan in hypertensive children 6 months to 5 years of age.
- New publicationRelation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
- New publicationValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.